Immuno-Oncology Therapy: The Power of Syngeneic Tumor Models
Leading the Charge in Immunotherapy Research & Discovery
In the transformative landscape of immuno-oncology, syngeneic mouse models have emerged as invaluable tools, allowing researchers to simulate and assess the dynamics of immunotherapies within an intact, fully functional immune environment. By grafting mouse tumor cell lines into genetically identical mouse strains, we maintain a responsive immune system.
TD2’s specialized syngeneic models stand out with:
- Comprehensive Characterization – Dive deep into gene expression, TIL baseline populations, and the intricate dance with leading immune checkpoint inhibitors.
- Consistent Microbial Landscape — With advanced 16S rRNA gene sequencing initiated pre-study, we ensure a consistent microbiome, guaranteeing your research is conducted within a known and unchanging host environment.
- Effector Cell Profiling — Through the precision of multi-parameter flow cytometry, we decode the changes in immune cell phenotypes post-treatment, setting the stage for more effective and tailored immuno-oncology therapy advancements.
Learn more about our syngeneic services.
Contact our experts to help advance your immunotherapy candidate with our trusted preclinical research services.
Available Syngeneic Models
Cancer Type | Syngeneic Line | Expression Data Available | ||||
---|---|---|---|---|---|---|
PD-1 | PD-L1 | PD-L2 | CTLA4 | Other | ||
Bladder | MB-49 MBT-2 |
|||||
Brain | GL261 | |||||
Breast | 4T1 4T1-Luc EMT-6 EO771 |
|||||
Colon | Colon 26-Luc colon 26 CT-26 MC-38 |
TIM-3, OX40 CD40 |
||||
Hematologic | EL-4 (Lymphoma) MPC-11 (Myeloma) |
Growth Kinetics Growth Kinetics |
||||
Hepatoma | Hepa 1-6 | |||||
Lung | KLN205 LL/2 LL/2-Luc TC-1 (HPV-Associated) |
Growth Kinetics | ||||
Ovarian | ID8-Luc | Growth Kinetics | ||||
Mastocytoma | P815 | Growth Kinetics | ||||
Pancreas | Pan02 Pan02 (Orthotopic) |
TIM-3, GITR | ||||
Renal | RENCA | |||||
Sarcoma | K7M2 (IV) | Growth Kinetics | ||||
Skin | B16-F1 B16-F10 B16-BL6 |
Figure 1. Growth curve response to standard of care treatments in orthotopic E0071 in C57BL/6 mice, subcutaneous MC38 in C57BL/6 mice, and subcutaneous CT-26 in balb/c mice in
E0771 Murine Breast Tumor Model
MC38 Murine Colon Tumor Model
CT-26 Murine Colon Tumor Model
IMMUNO-ONCOLOGY
Comprehensive preclinical services for immuno-oncology.
TD2’s extensive knowledge of CAR-T in both solid and hematologic tumors enables rapid evaluation of your CAR-T cell therapy, moving your therapeutic program forward to the clinic.
Large panel of human and murine tumor models
- 8 years of experience in cell therapy
- Expertise includes: CAR-T, NK-CAR, IPS-NKs, Macrophages
Humanized mice
- Human PBMCs or effector cell engraftment
- Sourced CD34+ humanized mice
- Humanized immune checkpoint inhibitor mice
GET STARTED
Work with a team who believes in your research as much as you do.
Are you ready to start your preclinical Adoptive Cell Transfer Therapy studies? Partner with a collaborative oncology CRO that believes in your treatment as much as you do. Take the first step today and contact our experts.